^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Malignant Pleural Mesothelioma |
| Drug: | carboplatin (Tubulin polymerization promoter) + Tomudex (raltitrexed) (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Recommendation 4...The first- and second-line treatment of unresectable mesothelioma...Anti-folate/platinum doublet is the only approved standard of care...Combination doublet chemotherapy of cisplatin, with either pemetrexed or raltitrexed, has shown a longer survival compared with cisplatin alone…Carboplatin is an acceptable alternative to cisplatin and may be better tolerated in the elderly population.
DOI:
doi:10.1093/annonc/mdv199
